The Cardioband mitral system is designed to safely and effectively reduce mitral
regurgitation through annular reduction.
Mitral regurgitation:
Treatment is complex and options are limited
Treatment is complex and options are limited
Mitral regurgitation (MR) occurs in approximately 2% of the population, with up to 10% of people over 75 years old affected.1
Medically managed patients with severe MR have poor outcomes.2
Individualised annular reduction
A CE Mark-approved transcatheter device designed to safely and effectively reduce mitral regurgitation through annular reduction3
Restores valve to a more functional state, facilitating leaflet coaptation
Enables annular reduction based on each patient’s anatomy
Supports real-time adjustment and confirmation of procedural results
A proven transseptal approach
The Cardioband mitral system is a transcatheter device designed to restore the mitral valve to a more functional state, facilitating leaflet coaptation and reducing mitral regurgitation.
-
Access
The Cardioband delivery system is inserted into the left ventricle using a transseptal approach. -
Deploy
individual anchors in a systematic, step-wise approach to conform the Cardioband implant to each patient's anatomy. -
Adjust and confirm
MR reduction in real time via transesophageal echo (TEE).
Excellent outcomes
Cardioband mitral system shows excellent outcomes in the CE Mark trial.4,5
Kaplan-Meier analysis
*Courtesy of Dr. Paul Grayburn, Baylor University, Houston, Texas, USA.
aMcNemar's test
bT-test
6MWT = 6-Minute Walk Test; MLHFQ = Minnesota Living with Heart Failure Questionnaire
bT-test
6MWT = 6-Minute Walk Test; MLHFQ = Minnesota Living with Heart Failure Questionnaire
Learn more
Learn more about the Cardioband mitral system.
Video library
Register for Cardioband mitral system updates
Sign up now to receive event information and news information from Edwards Lifesciences including:
- Publications
- Congress highlights
- Webinar invites
- Product announcements and updates
Learn more about Edwards' transcatheter mitral
and tricuspid portfolio
References:
- Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-1011.
- Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014;63:185-186.
- Vahanian A. Multicentre trial results of the transcatheter mitral valve repair system for functional mitral regurgitation. Presented at PCR London Valves, 2017.
- Transcatheter mitral valve repair in patients with functional mitral regurgitation: 2 year follow-up of the multicenter CE trial. Presented by Francesco Maisano, MD, PCR London Valves, 2018.
- Nickenig G. et al. Transcatheter Mitral Annuloplasty in Chronic Functional Mitral Regurgitation - 6-Month Results With the Cardioband Percutaneous Mitral Repair System. J Am Coll Cardiol Intv 2016;9:2039–47.
Please update your browser
Please update to a current version of your preferred browser, this site will perform effectively on the following:
If you are on a computer, that is maintained by an admin and you cannot install a new browser, ask your admin about it. If you can't change your browser because of compatibility issues, think about installing a second browser for browsing and keep this old one for compatibility
Content relating to Edwards Lifesciences devices is intended for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed, or click Decline to view non-device related content.